Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Gilead Hep-C pipeline drug hits speed bump: relapse in genotype 1 null responders

This article was originally published in Scrip

Executive Summary

Shares of Gilead Sciences took a dive after the company announced that in the genotype 1 null responder cohort of the ongoing Phase II ELECTRON study, certain patients relapsed within four weeks of completing 12 weeks on a two-drug regimen of Gilead's experimental hepatitis C drug GS-7977, a nucleoside analogue, plus ribavirin.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst